Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
3
43%
Ph phase_3
1
14%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_1

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

NCT04855136
completedphase_3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03651128
completedphase_2

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

NCT05032820
completedphase_2

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078
completedphase_2

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04855136Phase 1

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Terminated
NCT03651128Phase 3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Completed
NCT05032820Phase 2

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Completed
NCT03601078Phase 2

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Completed
NCT03361748Phase 2

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Completed
NCT04196491Phase 1

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Completed
NCT02658929Phase 1

Study of bb2121 in Multiple Myeloma

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7